Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
September 02, 2025 21:33 ET Â | Source: Mineralys Therapeutics, Inc. RADNOR, Pa.,…
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented…
